Exscientia (EXAI)
(Delayed Data from NSDQ)
$5.13 USD
0.00 (0.00%)
Updated May 16, 2024 04:00 PM ET
After-Market: $5.10 -0.03 (-0.58%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EXAI 5.13 0.00(0.00%)
Will EXAI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EXAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXAI
Brian's Big Idea on Healthcare
Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?
EXAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a Bet
Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?
Other News for EXAI
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
AI-discovered drugs have an 80%–90% success rate: study
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May